Antibody response to escherichia coli L-asparaginase

Prognostic significance and clinical utility of antibody measurement

Nai Kong V. Cheung, Irene Y. Chau, Peter Felix Coccia

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

By using a modification of The microtiter solid-phase radioimmunoassay, we have measured Escherichia coli L-asparaginase (L-ASP) specific IgG, IgG4, and IgE antibodies in children who received L-ASP as part of their chemotherapy for leukemia and lymphoma. In 13 children with acute lymphoblastic leukemia induced with vincristine, prednisone, and L-ASP (10,000 IU/M2 i.v. each week for 3 weeks), seven developed high titer specific IgG antibodies. Four of the seven relapsed at the time of their peaking IgG response (6-10 months). None of the six with low or absent L-ASP antibody response have relapsed (followed for 20-35 months). In six children with allergic reactions to L-ASP reinduction, all had high titers of L-ASP specific IgG4 (≥20 U/ml) at the time of their reaction. In 16 other children with low L-ASP IgG4 (<13 U/ml), none demonstrated allergic reactions to rechallenge. Specific IgE was not consistently detectable in either group. In 21 patients with leukemia or lymphoma on L-ASP with cyclophosphamide-containing regimens, none developed significant IgG antibody response, compared with seven of 13 not receiving cyclophosphamide (p < 0.001). We conclude: (a) development of L-ASP antibodies may have prognostic significance; (b) the detection of specific IgG4 can predict L-ASP allergy; and (c) cyclophosphamide-containing regimens reduce antibody formation to L-ASP and may allow repetitive (without anaphylaxis) and more effective (avoiding neutralizing antibodies) use of L-ASP.

Original languageEnglish (US)
Pages (from-to)99-104
Number of pages6
JournalAmerican Journal of Pediatric Hematology/Oncology
Volume8
Issue number2
StatePublished - Jan 1 1986

Fingerprint

Asparaginase
Antibody Formation
Escherichia coli
Antibodies
Immunoglobulin G
Cyclophosphamide
Hypersensitivity
Immunoglobulin E
Lymphoma
Leukemia
Vincristine
Anaphylaxis
Prednisone
Neutralizing Antibodies
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Radioimmunoassay

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Antibody response to escherichia coli L-asparaginase : Prognostic significance and clinical utility of antibody measurement. / Cheung, Nai Kong V.; Chau, Irene Y.; Coccia, Peter Felix.

In: American Journal of Pediatric Hematology/Oncology, Vol. 8, No. 2, 01.01.1986, p. 99-104.

Research output: Contribution to journalArticle

@article{bd7bf18fe0da4fa2b7e7597ba6b513b3,
title = "Antibody response to escherichia coli L-asparaginase: Prognostic significance and clinical utility of antibody measurement",
abstract = "By using a modification of The microtiter solid-phase radioimmunoassay, we have measured Escherichia coli L-asparaginase (L-ASP) specific IgG, IgG4, and IgE antibodies in children who received L-ASP as part of their chemotherapy for leukemia and lymphoma. In 13 children with acute lymphoblastic leukemia induced with vincristine, prednisone, and L-ASP (10,000 IU/M2 i.v. each week for 3 weeks), seven developed high titer specific IgG antibodies. Four of the seven relapsed at the time of their peaking IgG response (6-10 months). None of the six with low or absent L-ASP antibody response have relapsed (followed for 20-35 months). In six children with allergic reactions to L-ASP reinduction, all had high titers of L-ASP specific IgG4 (≥20 U/ml) at the time of their reaction. In 16 other children with low L-ASP IgG4 (<13 U/ml), none demonstrated allergic reactions to rechallenge. Specific IgE was not consistently detectable in either group. In 21 patients with leukemia or lymphoma on L-ASP with cyclophosphamide-containing regimens, none developed significant IgG antibody response, compared with seven of 13 not receiving cyclophosphamide (p < 0.001). We conclude: (a) development of L-ASP antibodies may have prognostic significance; (b) the detection of specific IgG4 can predict L-ASP allergy; and (c) cyclophosphamide-containing regimens reduce antibody formation to L-ASP and may allow repetitive (without anaphylaxis) and more effective (avoiding neutralizing antibodies) use of L-ASP.",
author = "Cheung, {Nai Kong V.} and Chau, {Irene Y.} and Coccia, {Peter Felix}",
year = "1986",
month = "1",
day = "1",
language = "English (US)",
volume = "8",
pages = "99--104",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Antibody response to escherichia coli L-asparaginase

T2 - Prognostic significance and clinical utility of antibody measurement

AU - Cheung, Nai Kong V.

AU - Chau, Irene Y.

AU - Coccia, Peter Felix

PY - 1986/1/1

Y1 - 1986/1/1

N2 - By using a modification of The microtiter solid-phase radioimmunoassay, we have measured Escherichia coli L-asparaginase (L-ASP) specific IgG, IgG4, and IgE antibodies in children who received L-ASP as part of their chemotherapy for leukemia and lymphoma. In 13 children with acute lymphoblastic leukemia induced with vincristine, prednisone, and L-ASP (10,000 IU/M2 i.v. each week for 3 weeks), seven developed high titer specific IgG antibodies. Four of the seven relapsed at the time of their peaking IgG response (6-10 months). None of the six with low or absent L-ASP antibody response have relapsed (followed for 20-35 months). In six children with allergic reactions to L-ASP reinduction, all had high titers of L-ASP specific IgG4 (≥20 U/ml) at the time of their reaction. In 16 other children with low L-ASP IgG4 (<13 U/ml), none demonstrated allergic reactions to rechallenge. Specific IgE was not consistently detectable in either group. In 21 patients with leukemia or lymphoma on L-ASP with cyclophosphamide-containing regimens, none developed significant IgG antibody response, compared with seven of 13 not receiving cyclophosphamide (p < 0.001). We conclude: (a) development of L-ASP antibodies may have prognostic significance; (b) the detection of specific IgG4 can predict L-ASP allergy; and (c) cyclophosphamide-containing regimens reduce antibody formation to L-ASP and may allow repetitive (without anaphylaxis) and more effective (avoiding neutralizing antibodies) use of L-ASP.

AB - By using a modification of The microtiter solid-phase radioimmunoassay, we have measured Escherichia coli L-asparaginase (L-ASP) specific IgG, IgG4, and IgE antibodies in children who received L-ASP as part of their chemotherapy for leukemia and lymphoma. In 13 children with acute lymphoblastic leukemia induced with vincristine, prednisone, and L-ASP (10,000 IU/M2 i.v. each week for 3 weeks), seven developed high titer specific IgG antibodies. Four of the seven relapsed at the time of their peaking IgG response (6-10 months). None of the six with low or absent L-ASP antibody response have relapsed (followed for 20-35 months). In six children with allergic reactions to L-ASP reinduction, all had high titers of L-ASP specific IgG4 (≥20 U/ml) at the time of their reaction. In 16 other children with low L-ASP IgG4 (<13 U/ml), none demonstrated allergic reactions to rechallenge. Specific IgE was not consistently detectable in either group. In 21 patients with leukemia or lymphoma on L-ASP with cyclophosphamide-containing regimens, none developed significant IgG antibody response, compared with seven of 13 not receiving cyclophosphamide (p < 0.001). We conclude: (a) development of L-ASP antibodies may have prognostic significance; (b) the detection of specific IgG4 can predict L-ASP allergy; and (c) cyclophosphamide-containing regimens reduce antibody formation to L-ASP and may allow repetitive (without anaphylaxis) and more effective (avoiding neutralizing antibodies) use of L-ASP.

UR - http://www.scopus.com/inward/record.url?scp=0022982465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022982465&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 99

EP - 104

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 2

ER -